Aura Biosciences
AURA
126 hedge funds and large institutions have $340M invested in Aura Biosciences in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 41 reducing their positions, and 12 closing their positions.
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
24% more capital invested
Capital invested by funds: $274M → $340M (+$66.6M)
8% more funds holding
Funds holding: 117 → 126 (+9)
1.02% more ownership
Funds ownership: 79.11% → 80.12% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 41
100% less call options, than puts
Call options by funds: $10K | Put options by funds: $2.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.2M |
| 2 |
Millennium Management
New York
|
+$2.76M |
| 3 |
CP
Caligan Partners
New York
|
+$1.32M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$479K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
-$1.96M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$721K |
| 3 |
LCS
Levin Capital Strategies
New York
|
-$541K |
| 4 |
RCAP
Resolute Capital Asset Partners
Denver,
Colorado
|
-$496K |
| 5 |
Barclays
London,
United Kingdom
|
-$331K |
AURA Hedge Fund Activity: Q1 2026 in Review
126 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2026, worth a combined $340M — up 24% from $274M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AURA positions and 12 closed out — a net gain of 11 holders — while 39 added to existing stakes and 41 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $3.2M. The largest seller was Decheng Capital, exiting entirely with an estimated $1.96M sold.
- 126 institutional investors held Aura Biosciences (AURA) as of Q1 2026, up from 117 in Q4 2025.
- Funds reported $340M of Aura Biosciences stock for Q1 2026, up 24% quarter-over-quarter.
- 23 funds opened new Aura Biosciences positions in Q1 2026 and 12 closed out, a net change of +11 holders.
- The largest Aura Biosciences buyer in Q1 2026 was Balyasny Asset Management, an estimated $3.2M added.
- The largest Aura Biosciences seller in Q1 2026 was Decheng Capital, an estimated $1.96M sold.
Based on aggregated 13F filings for Q1 2026.